Yale-New Haven Biotechnology Enterprise Forum Lecture Series Will Feature Expert in Financing of Biotechnology Companies

Mark Edwards, managing director at Recombinant Capital Inc. ReCap , a San Francisco-based consulting firm specializing in biotechnology business alliances, will speak on “Trends in Biotechnology Financing” on Tuesday, Jan. 27, from 4:30-6:30 p.m.

The talk, which is the third in the Yale-New Haven Biotechnology Enterprise Forum series, will be presented in Room B-79 of Watson Hall, 60 Sachem St., at the Yale School of Management. A panel discussion will follow his presentation and refreshments will be served in the foyer from 4-4:30 p.m.

Sponsored by The Biotech Committee of Greater New Haven and the Yale University Office of Cooperative Research, the lecture series focuses on commercial development of biotechnology and is geared toward entrepreneurs and university scientists. All talks in the series are open to the public free of charge.

Edwards has more than 14 years of experience in business development and licensing of biotechnology products. His firm is retained by 15 pharmaceutical companies and more than 100 biotech and service companies to advise on biotech alliances and valuations. ReCap’s publicly accessible web site http: recap.com mainweb.nsf is a widely used source of information about pharmaceutical and biotechnology industry developments.

Prior to founding ReCap in 1988, Edwards managed the Office of Business Development at Chiron Corp. He received his B.A. and M.B.A. degrees from Stanford University, where he also worked in the Office of Technology Licensing.

A panel discussion will follow Mr. Edward’s remarks. The panel will include David M. Cromwell, adjunct professor of entrepreneurship, Yale School of Management, formerly president and CEO of the private equity investment group at JPMorgan & Co. of New York; Roger Longman, managing partner, Windhover Information Inc., a Norwalk-based health-care business publishing and information company; Michael I. Sherman, president and CEO, Prostagen Inc., who has a Ph.D. in molecular biology and has started three biotechnology companies; and Elizabeth Silverman, senior research analyst focusing on genomics and new technologies related to drug discovery at BancAmerica Robertson Stephens.

Scheduled for future talks in the Yale-New Haven Biotechnology Enterprise Forum series are:

-March 3 – Jonathan Gorham, managing partner of Gorham Associates, will speak on “University-based Technology Incubators and Venture Funds” in Bass Hall, Bass Center for Molecular and Structural Biology, 266 Whitney Ave. He founded Gorham Associates in 1997, where he specializes in economic development consulting and management of innovation centers. He received his B.A. and M.A.T. degrees from Harvard University, and a master’s degree in public and private management from Yale University.

-April 7 – Gualberto Ruano, co-founder and chief executive officer of Genaissance, a New Haven-based biotechnology company focused on pharmacogenomics, will speak on “Genomic Strategies and Drug Discovery” in the Hope Conference Room, Sterling Hall of Medicine, 333 Cedar St. Dr. Ruano received a B.S. degree from Johns Hopkins University, a Ph.D. degree in human genetics from Yale, and his M.D. degree from the Yale University School of Medicine.

For more information, please call the Yale Office of Cooperative Research at 203 432-5446.

Share this with Facebook Share this with Twitter Share this with LinkedIn Share this with Email Print this